Published in Cancer Weekly, April 11th, 2000
"We provide data on in vivo targeting of the Thy 1.2 (CDw90) cell surface receptor expressed on neoplastic T cells, mouse EL4 T-cell lymphoma," wrote B. Rihova and colleagues, Academy Sciences Czech Republic, Institute Microbiology ("Polymeric drugs based on conjugates of synthetic and natural macromolecules. II. Anti-cancer activity of antibody or (Fab ')(2)-targeted conjugates and combined therapy with immunomodulators," Journal of Controlled Release,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.